Clinical trial
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years…
NCT00171184 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171184 |
|---|---|
| Title | Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder |
| Official title | Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder |
| Lead sponsor | Novartis, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Drug |
| Interventions | Darifenacin, Placebo |
| Enrollment | 400 |
| Start date | Apr 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | May 18, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: